Business
Pharmaceutical Verification Pilot
Pharmaceutical Verification Pilot.
About this update from Crimson Tide Plc
[{"type":"text","content":"\n \nRNS Number : 1316E Crimson Tide PLC 14 July 2016 \n\nCrimson Tide PLC\n \n(\"Crimson Tide\" or the 'Company')\n \nCrimson Tide selected for pharmaceutical verification pilot\n \nCrimson Tide (TIDE), the AIM-quoted provider of mpro5 - Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).\n \nSelected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer. The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards. The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.\n \nmpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information upload, quick verifications and multi-way data request transmittals.\n \nBarrie Whipp, Executive Chairman of Crimson Tide, said: \"The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world.\"\n \n‐ ends ‐\n \nFor further information: \n \nCrimson Tide plc \n \nBarrie Whipp  ...